Piperdi B - Search Results

1

Emerging treatment for advanced lung cancer with EGFR mutation.

Inal C, Yilmaz E, Piperdi B, Perez-Soler R, Cheng H. Inal C, et al. Among authors: piperdi b. Expert Opin Emerg Drugs. 2015;20(4):597-612. doi: 10.1517/14728214.2015.1058778. Epub 2015 Jul 8. Expert Opin Emerg Drugs. 2015. PMID: 26153235 Review.

2

Role of erlotinib in the treatment of non-small cell lung cancer: clinical outcomes in wild-type epidermal growth factor receptor patients.

Piperdi B, Perez-Soler R. Piperdi B, et al. Drugs. 2012 Jun 19;72 Suppl 1(0 1):11-9. doi: 10.2165/1163018-S0-000000000-00000. Drugs. 2012. PMID: 22712793 Free PMC article. Review.

3

The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib.

Zou Y, Ling YH, Sironi J, Schwartz EL, Perez-Soler R, Piperdi B. Zou Y, et al. Among authors: piperdi b. J Thorac Oncol. 2013 Jun;8(6):693-702. doi: 10.1097/JTO.0b013e31828c7210. J Thorac Oncol. 2013. PMID: 23575415 Free PMC article.

4

Targeting angiogenesis in squamous non-small cell lung cancer.

Piperdi B, Merla A, Perez-Soler R. Piperdi B, et al. Drugs. 2014 Mar;74(4):403-13. doi: 10.1007/s40265-014-0182-z. Drugs. 2014. PMID: 24578213 Free PMC article. Review.

5

First-in-human study of inhaled Azacitidine in patients with advanced non-small cell lung cancer.

Cheng H, Zou Y, Shah CD, Fan N, Bhagat TD, Gucalp R, Kim M, Verma A, Piperdi B, Spivack SD, Halmos B, Perez-Soler R. Cheng H, et al. Among authors: piperdi b. Lung Cancer. 2021 Apr;154:99-104. doi: 10.1016/j.lungcan.2021.02.015. Epub 2021 Feb 17. Lung Cancer. 2021. PMID: 33636454 Free PMC article.

6

Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell lines.

Piperdi B, Ling YH, Perez-Soler R. Piperdi B, et al. J Thorac Oncol. 2007 Aug;2(8):715-21. doi: 10.1097/JTO.0b013e3180f60bb3. J Thorac Oncol. 2007. PMID: 17762337 Free article.

7

Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).

Li T, Ho L, Piperdi B, Elrafei T, Camacho FJ, Rigas JR, Perez-Soler R, Gucalp R. Li T, et al. Among authors: piperdi b. Lung Cancer. 2010 Apr;68(1):89-93. doi: 10.1016/j.lungcan.2009.05.009. Epub 2009 Jun 12. Lung Cancer. 2010. PMID: 19524318 Clinical Trial.

8

Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer.

Piperdi B, Walsh WV, Bradley K, Zhou Z, Bathini V, Hanrahan-Boshes M, Hutchinson L, Perez-Soler R. Piperdi B, et al. J Thorac Oncol. 2012 Jun;7(6):1032-40. doi: 10.1097/JTO.0b013e31824de2fa. J Thorac Oncol. 2012. PMID: 22534815 Free PMC article. Clinical Trial.

9

Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment.

Cheng H, Shcherba M, Pendurti G, Liang Y, Piperdi B, Perez-Soler R. Cheng H, et al. Among authors: piperdi b. Lung Cancer Manag. 2014 Jan 1;3(1):67-75. doi: 10.2217/lmt.13.72. Lung Cancer Manag. 2014. PMID: 25342981 Free PMC article.

10

Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.

Ohri N, Piperdi B, Garg MK, Bodner WR, Gucalp R, Perez-Soler R, Keller SM, Guha C. Ohri N, et al. Among authors: piperdi b. Lung Cancer. 2015 Jan;87(1):23-7. doi: 10.1016/j.lungcan.2014.10.016. Epub 2014 Nov 6. Lung Cancer. 2015. PMID: 25468149

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

64 results

Search Page

Filters